Together, these data establish that expanded EC TIL products retain autologous tumor reactivity in an HLA-dependent manner, with both CD8+ and CD4+ subsets contributing to effector responses through distinct activation pathways (4-1BB vs. OX40) and potent Th1 cytokine production. The gene discussed is CD4; the disease is neoplasm.